Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.4K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.2K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent progresses in cancer multidrug resistance and therapeutic options associated with protein damage response.

Protein & cell·2026
Same author

RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.

Cell death & disease·2025
Same author

CDK4/6 Inhibition Induces CD8<sup>+</sup> T Cell Antitumor Immunity via MIF-Induced Functional Orchestration of Tumor-Associated Macrophages.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

CX1/BtSY2 and BANAL-20-52 exhibit broader receptor binding and higher affinities to multiple animal ACE2 orthologs than SARS-CoV-2 prototype.

Journal of virology·2025
Same author

Manipulation of magnetic edge states in carbon quantum dots for magnetic resonance imaging and NIR-II photo-thermoelectric therapy.

Nature communications·2025
Same author

Reciprocal stabilization of CtBP and TRIM28 represses autophagy to promote metastasis.

Nature structural & molecular biology·2025

Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K

Dasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling.

Xinyu Guo1,2, Heng Sun1,2,3, Feng Yu4

  • 1Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China.

Biomedicines
|December 30, 2025
PubMed
Summary

Dasatinib shows promise in treating aggressive triple-negative breast cancer (TNBC), especially the basal B subtype. This drug inhibits cancer cell migration and invasion by targeting ETS proto-oncogene 1 (ETS1) and matrix metalloproteinase-3 (MMP3).

Keywords:
ETS proto-oncogene 1 (ETS1)dasatinibextracellular matrixmatrix metalloproteinase-3 (MMP3)metastasistriple-negative breast cancer (TNBC)

More Related Videos

Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.1K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.6K

Related Experiment Videos

Last Updated: Jan 7, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K
Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.1K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.6K

Area of Science:

  • Oncology
  • Drug Discovery
  • Cancer Metastasis

Background:

  • Triple-negative breast cancer (TNBC), particularly basal B type, is highly invasive and metastatic.
  • Effective therapies for metastatic TNBC are urgently needed.
  • Understanding TNBC's underlying mechanisms is crucial for developing targeted treatments.

Purpose of the Study:

  • To identify effective therapeutic drugs for metastatic TNBC through drug repurposing.
  • To elucidate the mechanisms by which potential drugs inhibit TNBC invasion and metastasis.
  • To evaluate dasatinib as a therapeutic agent for aggressive TNBC.

Main Methods:

  • Systematic screening of 140 FDA-approved drugs using live-cell imaging wound-healing assays.
  • Validation of drug efficacy through in vitro invasion assays, in vivo models, and ex vivo organoid cultures.
  • Analysis of dasatinib's molecular mechanisms, including effects on the actin cytoskeleton, ETS1, and MMP3 expression.

Main Results:

  • Dasatinib demonstrated significant anti-cancer activity in aggressive TNBC, especially basal B type with high ETS proto-oncogene 1 (ETS1) expression.
  • Dasatinib disrupts the actin cytoskeleton, reduces cell motility, and suppresses ETS1 and matrix metalloproteinase-3 (MMP3) expression, inhibiting invasion.
  • A combination therapy of dasatinib with an anti-programmed cell death protein-1 (PD-1) antibody showed potential.

Conclusions:

  • Dasatinib is a potential therapeutic option for metastatic TNBC.
  • Targeting patients with high ETS1 expression may optimize dasatinib treatment response.
  • Further research into combination therapies, including with PD-1 inhibitors, is warranted.